Adaptate Biotherapeutics is a series a startup. 2 investors tracked. Status: possibledead.
Based in the United Kingdom, Adaptate Biotherapeutics is a startup. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Adaptate Biotherapeutics develops therapeutic antibodies to modulate the activity of gamma delta T cells, focusing on cancer treatments including both hematological and solid tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.